(Q36559414)

14 August 2017

1 reference

title

Raf kinases: oncogenesis and drug discovery (English)

1 reference

14 August 2017

1 reference

Ralf Schreck

1 reference

14 August 2017

Ulf R Rapp

series ordinal

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

International Journal of Cancer

14 August 2017

published in

1 reference

14 August 2017

volume

119

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

2261-2271

1 reference

Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus

14 August 2017

cites work

1 reference

Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611.

21 January 2018

1 reference

Nucleotide sequence of avian retroviral oncogene v-mil: homologue of murine retroviral oncogene v-raf

21 January 2018

1 reference

The RAF proteins take centre stage

21 January 2018

1 reference

Primary Structure of v- raf : Relatedness to the src Family of Oncogenes

21 January 2018

1 reference

Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins

21 January 2018

1 reference

raf family serine/threonine protein kinases in mitogen signal transduction.

21 January 2018

1 reference

Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus

21 January 2018

1 reference

Abrogation of IL-3 and IL-2 dependence by recombinant murine retroviruses expressing v-myc oncogenes

21 January 2018

1 reference

An altered v-raf is required in addition to v-myc in J3V1 virus for acceleration of murine plasmacytomagenesis

21 January 2018

1 reference

Transformation of murine bone marrow cells with combined v-raf-v-myc oncogenes yields clonally related mature B cells and macrophages

21 January 2018

1 reference

Mutational activation of c-raf-1 and definition of the minimal transforming sequence

21 January 2018

1 reference

Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase

21 January 2018

1 reference

Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1

21 January 2018

1 reference

Raf-1 activates MAP kinase-kinase

21 January 2018

1 reference

Activation of the MAP kinase pathway by the protein kinase raf

21 January 2018

1 reference

Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro

21 January 2018

1 reference

Characterization of murine A-raf, a new oncogene related to the v-raf oncogene

21 January 2018

1 reference

Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human

21 January 2018

1 reference

The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus

21 January 2018

1 reference

B-raf, a new member of the raf family, is activated by DNA rearrangement

21 January 2018

1 reference

The ins and outs of Raf kinases

21 January 2018

1 reference

Isotype-specific functions of Raf kinases

21 January 2018

1 reference

Mechanisms of regulating the Raf kinase family

21 January 2018

1 reference

Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors

21 January 2018

1 reference

Bcl-2 targets the protein kinase Raf-1 to mitochondria

21 January 2018

1 reference

Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1

21 January 2018

1 reference

Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1.

21 January 2018

1 reference

Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex

21 January 2018

1 reference

Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation

21 January 2018

1 reference

Second nature: biological functions of the Raf-1 "kinase"

21 January 2018

1 reference

Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.

21 January 2018

1 reference

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

21 January 2018

1 reference

Raf-1 regulates Rho signaling and cell migration

21 January 2018

1 reference

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

21 January 2018

1 reference

BuCy RAFs drive cells into MEK addiction

21 January 2018

1 reference

Back to the roots: the remarkable RAF oncogene story

21 January 2018

1 reference

Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration

21 January 2018

1 reference

A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity

21 January 2018

1 reference

A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila

21 January 2018

1 reference

Oligomerization activates c-Raf-1 through a Ras-dependent mechanism

21 January 2018

1 reference

Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization.

21 January 2018

1 reference

Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.

21 January 2018

1 reference

Regulation and role of Raf-1/B-Raf heterodimerization

21 January 2018

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

Forty years of cancer modelling in the mouse

21 January 2018

1 reference

New approaches for modelling cancer mechanisms in the mouse.

21 January 2018

1 reference

Mouse models of human cancer as tools in drug development.

21 January 2018

1 reference

B-raf and Ha-ras mutations in chemically induced mouse liver tumors

21 January 2018

1 reference

Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse

21 January 2018

1 reference

Raf kinases in lung tumor development

21 January 2018

1 reference

BAG-1 haplo-insufficiency impairs lung tumorigenesis

21 January 2018

1 reference

Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure

21 January 2018

1 reference

Bag1 is essential for differentiation and survival of hematopoietic and neuronal cells

21 January 2018

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

21 January 2018

1 reference

Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts

21 January 2018

1 reference

Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells

21 January 2018

1 reference

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

RAS oncogenes: the first 30 years.

21 January 2018

1 reference

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

21 January 2018

1 reference

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

21 January 2018

1 reference

Mutational analysis of the ARAF gene in human cancers.

21 January 2018

1 reference

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

21 January 2018

1 reference

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

21 January 2018

1 reference

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia

21 January 2018

1 reference

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

21 January 2018

1 reference

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome

21 January 2018

1 reference

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

21 January 2018

1 reference

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

Somatic alterations in the human cancer genome

21 January 2018

1 reference

The role of B-RAF in melanoma.

21 January 2018

1 reference

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs

21 January 2018

1 reference

BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer.

21 January 2018

1 reference

BRAF mutation in thyroid cancer

21 January 2018

1 reference

Origins and molecular pathology of ovarian cancer

21 January 2018

1 reference

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

Immunogenicity of constitutively active V599EBRaf

21 January 2018

1 reference

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

21 January 2018

1 reference

CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation

21 January 2018

1 reference

B-Raf specific antibody responses in melanoma patients

21 January 2018

1 reference

Raf kinase as a target for anticancer therapeutics

21 January 2018

1 reference

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery

21 January 2018

1 reference

A vision for the National Cancer Program in the United States

21 January 2018

1 reference

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

BAY 43-9006: preclinical data

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

BRAF is a therapeutic target in aggressive thyroid carcinoma.

21 January 2018

1 reference

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

21 January 2018

1 reference

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells

21 January 2018

1 reference

21 January 2018

1 reference

Raf-1 protein kinase is required for growth of induced NIH/3T3 cells

21 January 2018

1 reference

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo

21 January 2018

1 reference

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

21 January 2018

1 reference

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).

21 January 2018

1 reference

Comparison of strategies targeting Raf-1 mRNA in ovarian cancer

21 January 2018

1 reference

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies

21 January 2018

1 reference

Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.

21 January 2018

1 reference

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo

21 January 2018

1 reference

Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents

21 January 2018

1 reference

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone

21 January 2018

1 reference

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.

21 January 2018

1 reference

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

21 January 2018

1 reference

Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

21 January 2018

1 reference

In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

21 January 2018

1 reference

Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease

21 January 2018

1 reference

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin

21 January 2018

1 reference

Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity

21 January 2018

1 reference

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

Rational development of histone deacetylase inhibitors as anticancer agents: a review

21 January 2018

1 reference

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

21 January 2018

1 reference

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

Recent advances in tumour antigen-specific therapy: in vivo veritas

21 January 2018

1 reference

B-Raf and C-Raf signaling investigated in a simplified model of the mitogenic kinase cascade

21 January 2018

1 reference

Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway

21 January 2018

1 reference

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

21 January 2018

1 reference

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead

21 January 2018

1 reference

Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen

21 January 2018

1 reference

The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

21 January 2018

1 reference

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo

21 January 2018

1 reference

Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent

21 January 2018

1 reference

The discovery of potent cRaf1 kinase inhibitors

21 January 2018

1 reference

Paradoxical activation of Raf by a novel Raf inhibitor

21 January 2018

1 reference

Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation

21 January 2018

1 reference

Disruption of protein-protein interactions: towards new targets for chemotherapy

21 January 2018

1 reference

Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations

21 January 2018

1 reference

Bmi1, stem cells, and senescence regulation

21 January 2018

1 reference

MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1

21 January 2018

1 reference

Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.22144

1 reference

14 August 2017

1 reference